Overview

Vitiligo, New Treatment and Serum s100B

Status:
RECRUITING
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
vitiligo is an autoimmune depigmenting skin disorder characterized by milky white macules or patches, with 2% worldwide prevalence. Vitiligo has unexpected course that significantly influences on patient's quality of life and self-esteem. Multiple medications have been introduced for vitiligo treatment, in this study we work on one of systemic JAK inhibitors
Phase:
PHASE2
Details
Lead Sponsor:
South Valley University
Treatments:
baricitinib